The pel exopolysaccharide gene cluster of Pseudomonas aeruginosa
铜绿假单胞菌胞外多糖基因簇
基本信息
- 批准号:8757461
- 负责人:
- 金额:$ 45.02万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-07-17 至 2019-06-30
- 项目状态:已结题
- 来源:
- 关键词:AccountingAddressAmino SugarsAnabolismAnimal ModelAntibioticsBacteriaBiological AssayChemicalsChronicClinicalCommunitiesCystic FibrosisDataDevelopmentDiseaseEnvironmentExhibitsExtracellular MatrixFamily suidaeFeedbackFutureGene ClusterGenesGeneticGenotypeGoalsHost DefenseHumanIn VitroIndividualInfectionInterventionKnowledgeLeadLinkMicrobial BiofilmsModelingMolecularMorbidity - disease rateMusMutationPathogenesisPathway interactionsPhenotypePolysaccharidesPredispositionPrevalenceProductionPseudomonas aeruginosaQuality of lifeRelative (related person)RoleSignal TransductionStructureSurveysTherapeuticTherapeutic AgentsVariantantimicrobialbasebis(3&apos,5&apos)-cyclic diguanylic acidcystic fibrosis airwaycystic fibrosis patientsfitnessgenetic variantimprovedmortalitymucoidmutantneutrophilnoveloligoribonucleaseoutcome forecastphosphoric diester hydrolasepublic health relevanceresearch studysugartrait
项目摘要
DESCRIPTION (provided by applicant): Pseudomonas aeruginosa infections result in significant morbidity and mortality in people suffering from cystic fibrosis (CF). A key feature of
these infections is that they involve biofilm communities. Another is that during the course of chronic infection, P. aeruginosa acquires mutations that help it adapt to the CF environment. This proposal will investigate a clear link between biofilm formation and genetic adaptation, the RSCV phenotype. RSCVs generally exhibit increased biofilm formation and antimicrobial tolerance relative to the non- mucoid, smooth colony morphotype. One important trait of RSCVs are elevated production of the biofilm matrix exopolysaccharide PEL. The structure of PEL remains unknown, and its elucidation is a goal of this proposal. In addition, P. aeruginosa RSCVs are actively selected for during the course of chronic cystic fibrosis (CF) airway infections. We recently discovered that the prevalence of RSCVs in the CF airways has been grossly underestimated and we subsequently identified novel genetic loci linked to the RSCV phenotype. The molecular mechanism underpinning why these mutations produce RSCVs is unclear. Finally, we found that RSCVs can be highly variable phenotypically, depending upon the causal mutation. Some of these variable phenotypes are pathogenically relevant, suggesting that different RSCVs may vary in their ability to form biofilms and cause chronic infection. The overall goals of this application are to determine the structure of PEL and to elucidate the molecular mechanism leading to the RSCV phenotype that results from novel RSCV- linked mutations. We will also examine the pathogenic fitness advantages of different RSCV genotypes using chronic animal models of infection and in vitro cellular immunological assays. Once mucoid genetic variants of P. aeruginosa emerge, prognosis of CF patients clearly worsens. Thus, there exists a critical window of opportunity for immunological or chemotherapeutic intervention prior to mucoid conversion. RSCVs are usually observed prior to mucoidy, thus therapeutic strategies taking advantage of this window of opportunity would have to account for them. A thorough analysis of RSCVs and Pel may lead to the development of therapeutic agents and improve the quality of life for CF patients as well as individuals with other P. aeruginosa infections that involve biofilms.
描述(由申请人提供):铜绿假单胞菌感染导致囊性纤维化(CF)患者的显著发病率和死亡率。的一项关键功能
这些感染涉及到生物膜群落。另一种是,在慢性感染过程中,铜绿假单胞菌获得了帮助其适应CF环境的突变。这项建议将调查生物膜形成和遗传适应之间的明确联系,即RSCV表型。RSCV通常表现出与非粘液、光滑的菌落形态类型相比,生物被膜形成和抗菌素耐受性增加。RSCV的一个重要特征是提高了生物膜基质胞外多糖PEL的产量。PEL的结构仍不清楚,它的阐明是本提案的目标之一。此外,在慢性囊性纤维化(CF)呼吸道感染过程中,积极选择铜绿假单胞菌RSCV。我们最近发现,RSCV在慢性阻塞性肺疾病中的流行被严重低估,随后我们发现了与RSCV表型相关的新的遗传位点。这些突变产生RSCV的分子机制尚不清楚。最后,我们发现RSCV可以是高度可变的表型,这取决于因果突变。其中一些可变的表型在病原学上是相关的,这表明不同的RSCV在形成生物膜和导致慢性感染的能力上可能不同。这项应用的总体目标是确定PEL的结构,并阐明导致RSCV表型的分子机制,该表型是由RSCV连锁的新突变引起的。我们还将使用慢性动物感染模型和体外细胞免疫分析来检查不同RSCV基因型的致病适应性优势。一旦铜绿假单胞菌出现粘液型遗传变异,患者的预后明显恶化。因此,在粘液转化之前,存在一个关键的免疫或化疗干预的机会窗口。RSCV通常是在粘液样变之前观察到的,因此利用这个机会窗的治疗策略必须考虑到它们。对RSCV和PEL的彻底分析可能会导致治疗药物的开发,并改善CF患者以及其他涉及生物被膜的铜绿假单胞菌感染患者的生活质量。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MATTHEW R. PARSEK其他文献
MATTHEW R. PARSEK的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MATTHEW R. PARSEK', 18)}}的其他基金
Dispersion and the Biofilm Matrix of Pseudomonas aeruginosa
铜绿假单胞菌的分散和生物膜基质
- 批准号:
10376850 - 财政年份:2021
- 资助金额:
$ 45.02万 - 项目类别:
Dispersion and the Biofilm Matrix of Pseudomonas aeruginosa
铜绿假单胞菌的分散和生物膜基质
- 批准号:
10570255 - 财政年份:2021
- 资助金额:
$ 45.02万 - 项目类别:
The pel exopolysaccharide gene cluster of Pseudomonas aeruginosa
铜绿假单胞菌胞外多糖基因簇
- 批准号:
7653237 - 财政年份:2009
- 资助金额:
$ 45.02万 - 项目类别:
The pel exopolysaccharide gene cluster of Pseudomonas aeruginosa
铜绿假单胞菌胞外多糖基因簇
- 批准号:
8300158 - 财政年份:2009
- 资助金额:
$ 45.02万 - 项目类别:
The pel exopolysaccharide gene cluster of Pseudomonas aeruginosa
铜绿假单胞菌胞外多糖基因簇
- 批准号:
10609450 - 财政年份:2009
- 资助金额:
$ 45.02万 - 项目类别:
The pel exopolysaccharide gene cluster of Pseudomonas aeruginosa
铜绿假单胞菌胞外多糖基因簇
- 批准号:
7893711 - 财政年份:2009
- 资助金额:
$ 45.02万 - 项目类别:
The pel exopolysaccharide gene cluster of Pseudomonas aeruginosa
铜绿假单胞菌胞外多糖基因簇
- 批准号:
9102865 - 财政年份:2009
- 资助金额:
$ 45.02万 - 项目类别:
The pel exopolysaccharide gene cluster of Pseudomonas aeruginosa
铜绿假单胞菌胞外多糖基因簇
- 批准号:
8102041 - 财政年份:2009
- 资助金额:
$ 45.02万 - 项目类别:
The pel exopolysaccharide gene cluster of Pseudomonas aeruginosa
铜绿假单胞菌胞外多糖基因簇
- 批准号:
10376298 - 财政年份:2009
- 资助金额:
$ 45.02万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 45.02万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 45.02万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 45.02万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 45.02万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 45.02万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 45.02万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 45.02万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 45.02万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 45.02万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 45.02万 - 项目类别:
Research Grant














{{item.name}}会员




